AlphAIAlphAI — Financial news for AI agents
investing.com$DVA

DaVita shares tumble as earnings outlook disappoints

DaVita Inc (DVA) reported Q3 earnings of $3.82 per share, beating estimates, with revenue up 12.8% YoY. However, shares fell 9.5% after hours as full-year guidance of $14.30-$15.20 EPS missed expectations. The company cited modest U.S. dialysis growth and higher patient care costs. DVA also recorded a $62M impairment charge related to its China business and maintained its full-year free cash flow guidance.

Original reporting
investing.com
Published Oct 29, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DVA
Bearish
high confidence
Mentioned
$DVA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DVABearishMed
01

Why it matters

The key trading signal is the guidance midpoint coming in below consensus, which can dominate valuation even after an earnings beat. Investors will likely focus on whether patient care cost inflation and cash flow trends normalize in coming quarters.

02

Market read

A guidance-vs-consensus mismatch is driving an after-hours repricing for DVA, making near-term positioning sensitive to any follow-up commentary or analyst revisions.

03

What to watch

Cash flow declined year over year (operating and free cash flow), which could be a temporary working-capital or cost timing issue rather than a structural earnings reset.

Relevance 8/10Novelty 7/10Timing: after-hours Thursday reaction to full-year guidance

Background

DaVita’s Q3 results beat analyst expectations, but the market reaction centered on full-year adjusted diluted EPS guidance versus consensus.

Company-level read

Ticker impact

$DVABearishHigh confidence
Context

DaVita reported Q3 EPS and revenue beats but shares fell after-hours as full-year adjusted EPS guidance midpoint ($14.75) lagged consensus ($14.82).

Expected impact

Likely downside pressure as the market focuses on the unchanged but sub-consensus full-year EPS midpoint.

Evidence & confidence

The article attributes the after-hours drop to investor disappointment with full-year earnings guidance versus consensus, despite the quarter’s beat.

Market effects

Sector

Dialysis providers may see sentiment sensitivity to full-year EPS guidance versus consensus, even when quarterly results beat.

Regional

US healthcare services sentiment could soften modestly if guidance disappointments cluster.

Global

Limited direct global spillover; primarily a US-listed healthcare name repricing.

Counterpoint

What could challenge this read

The company kept its full-year guidance range unchanged, so the selloff may be driven more by consensus expectations than by deteriorating company fundamentals.

Key entities

  • company
    DaVita Inc

    US dialysis provider reporting Q3 results and unchanged full-year adjusted EPS guidance that disappointed investors.

  • executive
    Javier Rodriguez

    DaVita CEO quoted in the article.

Read at source← All news

StoryDaVita reports Q3 2026 earnings beat, raises full‑year EPS guidance and notes China impairment

Also covered by

6 outlets

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

finance.yahoo.com
$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

finance.yahoo.com
$DVAHighAI 9/10

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

finance.yahoo.com
$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

finance.yahoo.com
$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.

finance.yahoo.com